Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000176886 | SCV000228644 | likely pathogenic | not provided | 2013-12-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000176886 | SCV002132666 | uncertain significance | not provided | 2022-10-22 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change disrupts the translational stop signal of the OPA1 mRNA. It is expected to extend the length of the OPA1 protein by 13 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This protein extension has been observed in individuals with autosomal dominant optic atrophy (PMID: 16617242, 33841295). This variant is also known as Stop961Tyr, p.*1016Tyr. ClinVar contains an entry for this variant (Variation ID: 167406). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003987378 | SCV004804198 | uncertain significance | not specified | 2024-01-05 | criteria provided, single submitter | clinical testing | Variant summary: OPA1 c.2883A>C (p.X961TyrextX13) changes the termination codon and is predicted to lead to an extended protein with additional amino acids added to the normal C-terminus. The variant allele was found at a frequency of 6.6e-06 in 150998 control chromosomes (gnomAD v3.1). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. The variant, c.2883A>C, has been reported in the literature in at least 3 individuals affected with optic atrophy (Han_2006, Charif_2021), however no cosegregation evidence was provided. These reports therefore do not provide unequivocal conclusions about association of the variant with OPA1-Related Disorders. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. ClinVar contains an entry for this variant (Variation ID: 167406). Based on the evidence outlined above, the variant was classified as uncertain significance. |